Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy.
Lead Product(s): Tissue-engineered Autologous Outer Root Sheath Keratinocytes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Epidex
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Healiva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 01, 2022